ADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $35K of INM (indirect holdings)
ADAR1 Capital Management, LLC purchased 2,640 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at $13.10 on 2026-11-05. Filed jointly with Schneeberger Daniel (10% owner).
How this was made
The 30-second read
Why it matters
While the filing is new information, the modest dollar amount limits actionable insight.
Market read
Provides a fresh insider purchase record but unlikely to affect trading decisions materially.
What to watch
Potential upcoming clinical milestones for InMed could make the stake more meaningful.
Background
Form 4 filings disclose insider transactions; this filing reports a small open‑market purchase by a 10% owner.
Ticker impact
SEC Form 4 shows ADAR1 Capital Management purchased 2,640 shares of InMed Pharmaceuticals at $13.0953, total $34,571.59.
potential modest upward pressure as the market prices in insider buying
The transaction is a primary filing but involves only $35K, unlikely to move the stock significantly.
Market effects
Minimal effect on the biotech sector; insider activity is routine.
No regional impact.
Not globally relevant.
Counterpoint
The purchase could be a strategic stake, but the size suggests limited conviction.
Key entities
- companyInMed Pharmaceuticals Inc.
Biopharma company listed on Nasdaq under ticker INM.
- entityADAR1 Capital Management, LLC
Investment manager acting as a 10% owner of InMed.
